CureTech has revealed it has wrapped up a deal in which Teva
Pharmaceuticals will invest $6m (€4.7m) in CureTech, for the
development of a revolutionary cancer drug, based on the company's
potential value of $64m.
Contract biomanufacturing firm Laureate has won a contract to
produce Seattle Genetics' humanised monoclonal antibody product
candidates for clinical trial, adding to its experience in
monoclonal antibody development.
The drug trial catastrophe, which has endangered the lives of six
male volunteers of which two are still in a coma, could've been
avoided after a similar study conducted last year yielded similar
The worldwide market for therapeutic and diagnostic monoclonal
antibodies is expected to reach $26 million (€21.2 million) by
2010, buoyed on by technological advances that allow antibodies to
exhibit a specified targeted attack on...
GE Healthcare announced the launch of two new purification tools
designed to meet growing industry needs for the advancement of
monoclonal antibody (MAbs) research and development. The tools
become the latest offering in the chromatography...